pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior

Read the full 190 word article

User Sign In